Mentioned In
GLP Winner in the news and media
Knockoff weight loss drugs were supposed to be 'gone and illegal.' Now they're bigger than ever
Just weeks after regulators cracked down on these compounded weight loss drugs, the market for cheap alternatives to Ozempic and Eli Lilly's Zepbound is bigger than ever, according to Sabina Hemmi, who tracks pricing and providers in the GLP-1 market.
A new chapter for online sales of obesity drug alternatives tests legal limits
Hemmi, who founded a data company to help video gamers play better, started a website to help people sort through the mess. At first, it was just a listing of a few dozen companies and their prices. The website has since grown to include reviews and warnings about telehealth providers with ties to pharmacies cited for regulatory violations, for example.
Making Sense of Weight-Loss Drugs' Cost and Coverage
There are also price comparison sites the consumers can use. Sites such as GLP Winner and you can compare prices of brand-name GLP-1 drugs and get more information on some of the potential options.
The Price War in Weight-Loss Drugs Is Here
Makers Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines.
Patients Are Left With Few Options as GLP-1 Copycats Disappear
“There will be lots of options,” says Sabina Hemmi, who runs a startup called GLP Winner that allows patients to compare telehealth providers. “I think we'll see a lot more versions of the drugs that are taken by mouth, either dissolving or sublingual.”
Ozempic could redefine Thanksgiving across the country as users' appetites dwindle: 'I don't want to hurt anyone's feelings'
Sabina Hemmi, founder of GLP Winner, a platform that provides information about GLP-1 medications, suggested that family members should avoid making any comments if a loved one doesn’t seem as hungry as they once were.
GLP-1 users are becoming at-home chemists, mixing injections at home. Experts are worried.
Affordability and access drive "gray," says Sabina Hemmi, founder of GLP Winner, a consumer watchdog.
Say goodbye to gravy? Welcome to the Ozempic era of Thanksgiving
As GLP-1s go mainstream, it's more likely than not someone at your Thanksgiving table will look or eat differently, according to Sabina Hemmi, founder of GLP Winner, a GLP-1 watchdog